586 related articles for article (PubMed ID: 21342330)
1. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy.
Advani A; Wiggins KJ; Cox AJ; Zhang Y; Gilbert RE; Kelly DJ
Nephrology (Carlton); 2011 Aug; 16(6):573-81. PubMed ID: 21342330
[TBL] [Abstract][Full Text] [Related]
2. Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy.
Zhang M; Liu M; Xiong M; Gong J; Tan X
J Ethnopharmacol; 2012 May; 141(1):111-8. PubMed ID: 22353431
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes.
Wassef L; Kelly DJ; Gilbert RE
Kidney Int; 2004 Nov; 66(5):1805-14. PubMed ID: 15496151
[TBL] [Abstract][Full Text] [Related]
4. Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.
You H; Gao T; Raup-Konsavage WM; Cooper TK; Bronson SK; Reeves WB; Awad AS
Kidney Int; 2017 Mar; 91(3):671-682. PubMed ID: 27914709
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor.
Gilbert RE; Huang Q; Thai K; Advani SL; Lee K; Yuen DA; Connelly KA; Advani A
Kidney Int; 2011 Jun; 79(12):1312-21. PubMed ID: 21389970
[TBL] [Abstract][Full Text] [Related]
6. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318
[TBL] [Abstract][Full Text] [Related]
7. Podocyte hypertrophy precedes apoptosis under experimental diabetic conditions.
Lee SH; Moon SJ; Paeng J; Kang HY; Nam BY; Kim S; Kim CH; Lee MJ; Oh HJ; Park JT; Han SH; Yoo TH; Kang SW
Apoptosis; 2015 Aug; 20(8):1056-71. PubMed ID: 25953318
[TBL] [Abstract][Full Text] [Related]
8. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
[TBL] [Abstract][Full Text] [Related]
9. [The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy].
Wang S; Li Y; Huang YJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Sep; 27(9):1003-6. PubMed ID: 21906476
[TBL] [Abstract][Full Text] [Related]
10. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy.
Mifsud S; Kelly DJ; Qi W; Zhang Y; Pollock CA; Wilkinson-Berka JL; Gilbert RE
Nephron Physiol; 2003; 95(4):p83-91. PubMed ID: 14694265
[TBL] [Abstract][Full Text] [Related]
11. Tight blood glycaemic and blood pressure control in experimental diabetic nephropathy reduces extracellular matrix production without regression of fibrosis.
Conway BR; Betz B; Sheldrake TA; Manning JR; Dunbar DR; Dobyns A; Hughes J; Mullins JJ
Nephrology (Carlton); 2014 Dec; 19(12):802-13. PubMed ID: 25196678
[TBL] [Abstract][Full Text] [Related]
12. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
Jung E; Kim J; Ho Kim S; Kim S; Cho MH
Eur J Pharmacol; 2015 Aug; 761():116-24. PubMed ID: 25977232
[TBL] [Abstract][Full Text] [Related]
13. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
[TBL] [Abstract][Full Text] [Related]
14. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist.
Zhang Y; Deb DK; Kong J; Ning G; Wang Y; Li G; Chen Y; Zhang Z; Strugnell S; Sabbagh Y; Arbeeny C; Li YC
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F791-801. PubMed ID: 19535571
[TBL] [Abstract][Full Text] [Related]
15. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.
Deb DK; Sun T; Wong KE; Zhang Z; Ning G; Zhang Y; Kong J; Shi H; Chang A; Li YC
Kidney Int; 2010 Jun; 77(11):1000-9. PubMed ID: 20182412
[TBL] [Abstract][Full Text] [Related]
16. FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats.
Sanajou D; Ghorbani Haghjo A; Argani H; Roshangar L; Ahmad SNS; Jigheh ZA; Aslani S; Panah F; Rashedi J; Mesgari Abbasi M
J Physiol Biochem; 2018 Aug; 74(3):467-478. PubMed ID: 29948786
[TBL] [Abstract][Full Text] [Related]
17. Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis.
Herbach N; Schairer I; Blutke A; Kautz S; Siebert A; Göke B; Wolf E; Wanke R
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F819-29. PubMed ID: 19211686
[TBL] [Abstract][Full Text] [Related]
18. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
Gross ML; El-Shakmak A; Szábó A; Koch A; Kuhlmann A; Münter K; Ritz E; Amann K
Diabetologia; 2003 Jun; 46(6):856-68. PubMed ID: 12802493
[TBL] [Abstract][Full Text] [Related]
19. The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy.
Tunçdemir M; Oztürk M
Acta Histochem; 2011 Dec; 113(8):826-32. PubMed ID: 21269661
[TBL] [Abstract][Full Text] [Related]
20. Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
Zhou G; Cheung AK; Liu X; Huang Y
Clin Sci (Lond); 2014 May; 126(10):707-20. PubMed ID: 24195695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
